Literature DB >> 23642658

The diverse therapeutic actions of pregabalin: is a single mechanism responsible for several pharmacological activities?

Stephen M Stahl1, Frank Porreca, Charles P Taylor, Raymond Cheung, Andrew J Thorpe, Andrew Clair.   

Abstract

Pregabalin is a specific ligand of the alpha2-delta (α2-δ) auxiliary subunit of voltage-gated calcium channels. A growing body of evidence from studies of anxiety and pain indicate that the observed responses with pregabalin may result from activity at the α2-δ auxiliary protein expressed presynaptically, in several different circuits of the central nervous system (CNS). The disorders that appear to be effectively treated with pregabalin are thematically linked by neuronal dysregulation or hyperexcitation within the CNS. This review proposes how binding to the α2-δ protein target in different regions of the CNS may contribute to the observed clinical activity of pregabalin, as well as to the adverse event profile of the compound. Whether this compound regulates synaptic function via α2-δ in additional conditions is yet to be discovered. The potential of pregabalin to regulate neuronal hyperactivity involving other CNS circuits will require further exploration.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23642658     DOI: 10.1016/j.tips.2013.04.001

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  27 in total

1.  Refractory social anxiety disorder.

Authors:  Michael Van Ameringen; Beth Patterson
Journal:  J Psychiatry Neurosci       Date:  2017-01       Impact factor: 6.186

2.  Investigation of the predictive validity of laser-EPs in normal, UVB-inflamed and capsaicin-irritated skin with four analgesic compounds in healthy volunteers.

Authors:  Klaus Schaffler; Laurent B Nicolas; Andreas Borta; Tobias Brand; Peter Reitmeir; Robert Roebling; Joachim Scholpp
Journal:  Br J Clin Pharmacol       Date:  2017-02-27       Impact factor: 4.335

Review 3.  Pain pharmacology: focus on opioids.

Authors:  Diego Fornasari
Journal:  Clin Cases Miner Bone Metab       Date:  2014-09

Review 4.  Diabetic neuropathic pain: Physiopathology and treatment.

Authors:  Anne K Schreiber; Carina Fm Nones; Renata C Reis; Juliana G Chichorro; Joice M Cunha
Journal:  World J Diabetes       Date:  2015-04-15

5.  Anxiolytic effects of the novel α2δ ligand mirogabalin in a rat model of chronic constriction injury, an experimental model of neuropathic pain.

Authors:  Hiroyasu Murasawa; Hiroyuki Kobayashi; Kensuke Saeki; Yutaka Kitano
Journal:  Psychopharmacology (Berl)       Date:  2019-09-12       Impact factor: 4.530

6.  The effect of pregabalin and celecoxib on the analgesic requirements after laparoscopic cholecystectomy: a randomized controlled trial.

Authors:  Usha Gurunathan; Ivan L Rapchuk; Gillian King; Adrian G Barnett; John F Fraser
Journal:  J Anesth       Date:  2015-09-29       Impact factor: 2.078

Review 7.  Mechanisms of Action of Antiseizure Drugs and the Ketogenic Diet.

Authors:  Michael A Rogawski; Wolfgang Löscher; Jong M Rho
Journal:  Cold Spring Harb Perspect Med       Date:  2016-05-02       Impact factor: 6.915

8.  The monoacylglycerol lipase inhibitor KML29 with gabapentin synergistically produces analgesia in mice.

Authors:  Molly S Crowe; Catheryn D Wilson; Emma Leishman; Paul L Prather; Heather B Bradshaw; Matthew L Banks; Steven G Kinsey
Journal:  Br J Pharmacol       Date:  2017-11-20       Impact factor: 8.739

Review 9.  Stem Cell Therapy for Modulating Neuroinflammation in Neuropathic Pain.

Authors:  Hari Prasad Joshi; Hyun-Jung Jo; Yong-Ho Kim; Seong-Bae An; Chul-Kyu Park; Inbo Han
Journal:  Int J Mol Sci       Date:  2021-05-03       Impact factor: 5.923

10.  Electroacupuncture prevents cocaine-induced conditioned place preference reinstatement and attenuates ΔFosB and GluR2 expression.

Authors:  Ai T M Nguyen; Tran V B Quach; Peddanna Kotha; Szu-Yu Chien; Iona J MacDonald; Hsien-Yuan Lane; Cheng-Hao Tu; Jaung-Geng Lin; Yi-Hung Chen
Journal:  Sci Rep       Date:  2021-07-01       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.